Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Executive Changes (May 22, 2025)

Reports
Leadership Changes·Shareholder Matters
Filing Date
Filed May 22, 2025
Period End
May 21, 2025
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed May 22, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported in this Form 8-K, filed May 22, 2025, the results of its 2025 Annual Meeting of Stockholders, held May 21, 2025.

The record date was March 24, 2025, when 98,938,234 shares of common stock were entitled to vote. Holders of 90,434,193 shares were present in person or by proxy. Under Item 5.02(e), stockholders approved the company's 2025 Equity Incentive Plan (the "2025 Plan") and an amendment and restatement of the 2018 Employee Stock Purchase Plan (the "Amended and Restated ESPP").

The filing incorporates by reference the summary of these plans' material terms in the definitive proxy statement filed with the SEC on April 9, 2025. Stockholders elected four Class II Directors to three-year terms expiring at the 2028 Annual Meeting: Kyle W. Gano, Ph.D., Richard F.

Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. Richard F.

Pops drew the most votes withheld at 12,809,685, while Kyle W. Gano, Ph.D. drew the fewest at 1,382,673. Class III directors Kevin C.

Gorman, Ph.D., Gary A. Lyons, and Johanna Mercier continue until the 2026 meeting, and Class I directors William H. Rastetter, Ph.D., George J.

Morrow, Leslie V. Norwalk, and Christine A. Poon continue until the 2027 meeting.

The advisory say-on-pay proposal was approved, with 77,981,925 votes for and 6,070,336 against. The 2025 Plan received 72,648,862 votes for and 12,884,104 against, and was approved. The Amended and Restated ESPP received 85,402,588 votes for and 138,042 against, and was approved.

Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for and 5,179,700 against. Broker non-votes totaled 4,705,420 on the director, say-on-pay, and 2025 Plan items.

Key Highlights

  1. Stockholders approved the 2025 Equity Incentive Plan, with 72,648,862 votes for and 12,884,104 votes against.
  2. Stockholders approved the Amended and Restated 2018 Employee Stock Purchase Plan, with 85,402,588 votes for and 138,042 votes against.
  3. Four Class II Directors were elected to terms expiring at the 2028 Annual Meeting: Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D.
  4. The advisory vote on named executive officer compensation was approved, with 77,981,925 votes for and 6,070,336 votes against.
  5. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for and 5,179,700 votes against.
  6. Of 98,938,234 shares entitled to vote at the March 24, 2025 record date, 90,434,193 shares were present at the May 21, 2025 Annual Meeting.
  7. Richard F. Pops received 12,809,685 votes withheld, the largest withhold count among the four director nominees.

Frequently Asked Questions

  1. What equity compensation plan did stockholders approve at the 2025 Annual Meeting?

    Stockholders approved the Company's 2025 Equity Incentive Plan (the "2025 Plan"), with 72,648,862 votes for, 12,884,104 votes against, 195,807 abstentions, and 4,705,420 broker non-votes. The filing incorporates by reference the summary of its material terms from the proxy statement filed April 9, 2025.

  2. Did stockholders approve changes to the employee stock purchase plan?

    Yes. Stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan, with 85,402,588 votes for, 138,042 against, 188,143 abstentions, and 4,705,420 broker non-votes.

  3. Who was elected to the board, and when do their terms expire?

    Kyle W. Gano, Ph.D., Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D. were elected as Class II Directors for three-year terms expiring at the 2028 Annual Meeting. Class III directors Kevin C. Gorman, Ph.D., Gary A. Lyons, and Johanna Mercier continue until the 2026 Annual Meeting, and Class I directors William H. Rastetter, Ph.D., George J. Morrow, Leslie V. Norwalk, and Christine A. Poon continue until the 2027 Annual Meeting.

  4. How did stockholders vote on executive pay and the auditor?

    The advisory say-on-pay vote was approved, with 77,981,925 votes for, 6,070,336 against, and 1,676,512 abstentions. Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for, 5,179,700 against, and 235,144 abstentions.